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Abstract
This brief summarizes a new systematic review of economic evaluations of treatments for substance use
disorders. The review reveals strong evidence that methadone maintenance therapy is an economically
advantageous form of treatment; the economic evidence for buprenorphine and naltrexone treatments is
more limited.
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Opioid misuse has reached epidemic proportions in the United States. According to the Centers for Disease Control and Prevention (CDC), in 2014 more than 
18,900 people died from an overdose of prescription pain relievers and 10,575 
people died from an overdose of heroin, which amounts to 78 Americans dying 
from opioid overdose each day. The societal costs associated with opioid misuse 
may be as high as $92 billion annually, when health care, labor, and criminal justice 
costs are taken into account.  
The Administration’s proposed budget for 2017 includes more than $1 billion for 
fighting this epidemic, with $920 million to support cooperative agreements with 
states to expand access to medication-assisted treatment for opioid use disorders. 
While the final budgeted amount will be a product of negotiations with Congress, 
there is bipartisan support for significant sums devoted to treatment. Policymakers 
now face the key question of how best to spend this money, considering 
treatments that are both clinically and cost effective. This Issue Brief discusses 
treatments for opioid use disorders and summarizes a new systematic review of 
economic evaluations of these interventions.  
Upfront: Only 10% of individuals with an opioid use disorder receive any 
therapy at all
 
In a comprehensive literature review, Murphy and Polsky (2016) summarized 49 
studies from 2007 through 2015 that included an economic evaluation of an opioid 
use disorder intervention. Their findings come with an important caveat, because 
only 10% of individuals with an opioid use disorder receive any therapy at all.  They 
note that the existing economic literature does not answer a simple yet 
fundamental question: what is the cost effectiveness of just offering effective 
opioid use disorder therapy? It could be that expanding access to different kinds of 
treatment brings more people into treatment itself, which may be a cost effective 
strategy. This is important to keep in mind because most economic evaluations 
have compared alternative therapies, as opposed to evaluating the impact of 
making any treatment available to the 90% of patients with an opioid use 
disorder who are not currently in treatment.
This issue Brief discusses 
TreaTmenTs for opioid use 
disorders and summarizes a 
new sysTemaTic review of 
economic evaluaTions of 
These inTervenTions.
Center for Health Economics of Treatment Interventions for
Substance Use Disorder, HCV, and HIV
May 2016 - Issue Brief
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Opioid use disorder therapies: What’s effective
 
Effective interventions for opioid use disorders are available and fall into two broad 
categories: psychosocial and pharmacological.  Psychosocial therapies include 
cognitive behavioral therapies, relapse prevention, contingency management 
(reinforcing desired behaviors and not reinforcing undesired behaviors), and 
motivational enhancement. These therapies can be used by themselves or in 
combination with pharmacological therapy.  
Pharmacotherapies vary in the degree to which they mimic, or block, the euphoric 
effects of opioids.  Methadone, a long-acting opioid, activates opioid receptors in 
the brain, reducing pain, cravings, and withdrawal symptoms without producing 
the full euphoric effects of illicit or prescription opioids.  Buprenorphine, a partial 
opioid agonist, activates opioid receptors in the brain to a lesser extent, which 
minimizes the symptoms of withdrawal and cravings. Maintenance therapy with 
methadone or buprenorphine is widely regarded as an effective form of therapy. 
Both can also be used to assist with short-term detoxification (medically-supervised 
withdrawal). Because they are controlled substances with the potential for abuse, 
they are highly regulated. Although not commonly used in the United States, 
injectable heroin is another form of pharmacotherapy used in Canada and the 
United Kingdom for opiate dependent persons who do not benefit from or cannot 
tolerate other opiate replacement treatments.  
In contrast, antagonists, such as naloxone and naltrexone, block opioid brain 
receptors and have the advantage of being non-narcotic and non-addictive. 
Because antagonists block these receptors, they can cause withdrawal symptoms 
if taken by an individual physically dependent on opioids. Naloxone is used as a 
rescue medication for opioid overdose and is not used alone in the treatment of 
opioid dependence. Naloxone is typically combined with buprenorphine to reduce 
the likelihood that buprenorphine will be diverted (illicit drugs being used for illicit 
purposes) or misused.  
Providers have varying abilities to prescribe these pharmacotherapies to treat 
opioid use disorder.  Buprenorphine is only available by specially trained and 
licensed physicians and methadone is only available at specialty clinics. In contrast, 
naloxone and naltrexone can be prescribed by any provider who is licensed to 
prescribe medications. Additionally, naloxone can be administered by non-medical 
personnel and, in some states, is available at pharmacies without a prescription.  
Given that policymakers must make decisions on how to allocate scarce resources, 
evidence of effectiveness for the treatment of opioid use disorder is not enough—
nor should it be.  Economic evaluations can provide evidence to help guide 
decisions to allocate public resources efficiently and effectively. 
New systematic review finds pharmacotherapy is associated with lower 
total health care costs
 
In their review, Murphy and Polsky found that 30% of the studies focused on 
comparing health care use and costs associated with different kinds of treatments. 
despiTe higher ouTpaTienT 
or prescripTion cosTs, 
pharmacoTherapy for 
opioid use disorders is 
associaTed wiTh lower 
ToTal healTh care cosTs.
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Overall, they found that in spite of higher outpatient or prescription costs, pharma-
cotherapy for opioid use disorders is associated with lower total health care costs, 
primarily due to lower utilization of high-cost services such as emergency  
department (ED) visits and inpatient care.
• A study comparing health plan beneficiaries on MMT with those receiving 
non-methadone outpatient treatment found that patients on MMT had 
lower health care costs ($7,163 in 2004 USD) than patients with two or more 
non-methadone outpatient visits ($14,157) and patients with zero or one 
non-methadone outpatient visits ($18,684). The relatively low cost for MMT 
patients was due to fewer ED and primary care visits, and fewer inpatient 
stays.
Studies comparing different pharmacotherapies show that methadone  
maintenance therapy (MMT) patients tend to use more health care resources and 
have higher health care costs than patients receiving buprenorphine-naloxone 
maintenance therapy (BMT), at least in the short-term (six months).
• One study also showed at six months post treatment, MMT patients were 
significantly more expensive than patients being treated with oral naltrexone 
and extended-release naltrexone.
• A number of studies compared total health care costs of different BMT 
approaches and dosage forms. Patients receiving BMT and psychosocial 
therapy had similar costs to those receiving psychosocial therapy only, and 
lower costs than those receiving little or no treatment. Other studies found 
lower costs associated with buprenorphine-naloxone film versus tablets, and 
improved retention in treatment for high-dose versus low-dose buprenor-
phine-naloxone patients, with no increase in total health care costs. 
MMT and BMT are cost effective by US standards for treatments, 
although evidence for BMT and naltrexone is more limited
 
Policymakers are keenly interested in cost offsets, in terms of both health care and 
criminal justice-related costs, but also want to know what these scarce resources 
are buying in terms of outcomes. Murphy and Polsky reviewed 30 studies that 
addressed both the costs and benefits of pharmacotherapy. A key challenge in 
translating cost-benefit and cost-effectiveness research for policymakers is how to 
standardize outcomes, which can encompass abstinence rates, opioid-free days, 
quality of life measures, and benefit-cost ratios. The most frequently used 
measure is the quality-adjusted life-year (QALY), which standardizes outcomes 
across conditions and treatments.  A traditional, though informal, US threshold 
for a cost effective intervention has been $50,000 per QALY gained, although 
$100,000/QALY has become more accepted recently.  
By the $50,000 per QALY standard, multiple studies found that MMT and BMT 
would be considered cost effective relative to no pharmacotherapy. However,  
other studies calculated much smaller incremental cost-effectiveness gains. 
Relative to MMT, extended-release naltrexone had a cost-effectiveness ratio of $72 
(in 2014 USD) per opioid free day. Relative to naltrexone, BMT had cost-effective-
ness ratios less than $50 (in 2004 USD) for a host of primary outcomes, including 
heroin abstinence and days to relapse. But the authors stress that there are no 
accepted standards upon which to judge these alternate values. 
evidence ThaT mmT is 
economically 
advanTageous is sTrong; 
economic evidence on 
BmT is limiTed BuT 
promising.
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MMT may be more cost effective than BMT, but both are better than no 
pharmacotherapy
 
Twelve studies focused on MMT, relative to residential therapy or outpatient 
non-pharmacological treatments, and two others assessed MMT or BMT relative 
to an outpatient non-pharmacological alternative. Several studies compared MMT 
with other pharmacological therapies, including injectable heroin and naltrexone.  
• Cost-effectiveness and cost-benefit studies comparing MMT and BMT  
generally favored MMT, but both are cost effective relative to no treatment 
or drug-free treatment. A study of Medicaid patients found that those 
receiving either BMT or MMT were 50% less likely to relapse than those 
receiving behavioral treatments only. MMT and BMT patients had mean 
monthly health care costs that were $184-$191 less than those receiving 
behavioral treatment only.  
• In one study using modeling to predict cost-effectiveness, extended-release 
naltrexone was predicted to be more effective, and also more costly, than 
MMT and BMT.
• Overall, abstinence rates were statistically similar for BMT and MMT, but 
MMT was less expensive. MMT had better six-month patient retention rates 
than BMT, but BMT was more effective in terms of detox rates. MMT was 
more cost effective than BMT in terms of opioid-free days.  
• In one Canadian study injectable heroin was found to be more cost  
effective than MMT, but a UK study found that injectable heroin was slightly 
less cost effective than injectable methadone.  Of note, the savings  
attributed to injectable treatments were associated with the criminal justice 
system; injectable forms of both heroin and methadone were cost  
ineffective from the National Health Service perspective.  
• In studies comparing BMT with no treatment, short-term detoxification, and 
naltrexone alone, the results generally favored BMT.
Limited cost-effectiveness evidence on contingency management, other 
implementation strategies
 
Two studies looked at the cost effectiveness of contingency management (CM) with 
prizes or vouchers as an add-on to usual treatment for patients with opioid use 
disorders.  Both used the longest duration of abstinence and the number of  
negative urine samples as outcome measures, and calculated incremental cost 
effectiveness as $212 per week of abstinence and $156 per negative urine sample. 
Murphy and Polsky stress that there are no generally-accepted cost-effectiveness 
thresholds for outcomes of this sort.  A recent article by the same authors assessed 
an internet-delivered CM intervention for substance use disorders, and found that 
it was likely cost-effective based on the clinical outcome of abstinence.
A few studies looked at the cost effectiveness of implementation strategies.  One 
study found unobserved dosing of BMT was more advantageous than observed 
dosing, because it was found to be less expensive with no significant differences in 
days of heroin use, quality of life, or psychological state.  Another study found MMT 
programs that were highly concordant with clinical practice guidelines were more 
expensive, on average, than less concordant programs but were more effective 
with regard to therapy sessions completed, abstinence and quality-of-life scores. 
The auThors find ThaT 
The economic evidence on 
BmT and nalTrexone 
TreaTmenTs is limiTed. 
however, The resulTs are 
promising for BmT, as 
well as for conTingency 
managemenT approaches 
and cerTain Therapy 
implemenTaTion sTraTegies.
Conclusion
 
The latest systematic review reveals strong evidence that MMT is an economically 
advantageous form of treatment for opioid use disorders. The authors find that the 
economic evidence on BMT and naltrexone or extended-release naltrexone  
treatments is limited. However, the results are promising for BMT, as well as for 
contingency management approaches and certain therapy implementation  
strategies. Much more research is needed to better evaluate the relative cost 
effectiveness of these common opioid use disorder therapies.  Evaluations directly 
comparing MMT to other pharmacological treatments and analyses assessing  
treatment versus no treatment are needed.  As policymakers and practitioners 
grapple with the fallout of the opioid epidemic, these economic evaluations are 
critical in a time where limited resources must be stretched over a large, and 
growing population. Researchers, in turn, may need to hear from policymakers 
about the cost-effectiveness measures most likely to be useful in the policymaking 
process. 
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more research is needed 
To BeTTer evaluaTe The 
relaTive cosT effecTiveness 
of These common opioid use 
disorder Therapies.
